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Purpose: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death 
worldwide and is associated with a growing and substantial socioeconomic burden. Long-term 
oxygen therapy (LTOT), recommended by current treatment guidelines for COPD patients with 
severe chronic hypoxemia, has shown to reduce mortality in this population. The aim of our 
study was to assess the standardized mortality ratios of incident and prevalent LTOT users and 
to identify predictors of mortality.
Patients and methods: We conducted a 2-year follow-up population-based cohort study 
comprising all COPD patients receiving LTOT in the canton of Bern, Switzerland. Comparing 
age- and sex-adjusted standardized mortality ratios, we examined associations between all-cause 
mortality and patient characteristics at baseline. To avoid immortal time bias, data for incident 
(receiving LTOT ,6 months) and prevalent users were analyzed separately.
Results: At baseline, 475 patients (20% incident users, n=93) were receiving LTOT because 
of COPD (48/100,000 inhabitants). Mortality of incident and prevalent LTOT users was 41% 
versus 27%, respectively, p,0.007, and standardized mortality ratios were 8.02 (95% CI: 
5.64–11.41) versus 5.90 (95% CI: 4.79–7.25), respectively. Type 2 respiratory failure was 
associated with higher standardized mortality ratios among incident LTOT users (60.57, 95% CI: 
11.82–310.45, p=0.038).
Conclusion: Two-year mortality rate of COPD patients on incident LTOT was somewhat 
lower in our study than in older cohorts but remained high compared to the general population, 
especially in younger patients receiving LTOT ,6 months. Type 2 respiratory failure was 
associated with mortality.
Keywords: COPD, long-term oxygen therapy, mortality, type 2 respiratory failure
Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death 
worldwide and is associated with a substantial and growing socioeconomic burden.1 
It is projected that mortality from COPD will continuously increase and become the 
world’s third leading cause of mortality by 2030.2 Disease progression usually leads 
to severe hypoxemia, presenting with symptoms such as dyspnea, reduced exercise 
tolerance, daytime fatigue and sleepiness, impaired intellectual faculties, anxiety and 
depression. Long-term oxygen therapy (LTOT) has been found to reduce overall 
mortality and to improve cognitive function and emotional status in COPD patients 
with severe chronic hypoxemia and is recommended for this population by current 
treatment guidelines.1,3–6 Survival of such patients remains poor despite LTOT. The 
overall age-standardized COPD mortality ratio for men and women in Europe is about 
18 per 100,000 per year with a great variability across different countries.7 Factors 
associated with mortality in patients with severe COPD include age, sex, lung function, 
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malnutrition, concomitant malignancy, smoking habits, 
hypoxemia and exercise tolerance.8
The presence of severe hypoxemia in many patients 
with end-stage COPD requiring supplemental oxygen easily 
explains the association of LTOT with a higher mortality.9–11 
However, only few studies addressed mortality in this 
subgroup of patients. Mortality rates of patients receiving 
LTOT vary between 12% and 31% after 1 year, between 
22% and 62% after 2 years and between 36% and 81% after 
5 years.8,12–19 There is inconsistent data on the sex-related 
differences in survival on LTOT for COPD as well as on 
the association of hypercapnia with excess mortality. Lower 
body mass index, subjective intensity of dyspnea, severity of 
hypoxemia and comorbidities at baseline proved to be predic-
tors of higher mortality in patients with LTOT.8,15–17,20–24
A better understanding of the natural course of COPD at 
its end stage and identification of potentially modifiable risk 
factors for excess mortality could improve patient manage-
ment and give insight for novel care strategies for patients 
with COPD on LTOT. We aimed at calculating population-
based estimates of overall mortality and standardized mor-
tality ratios of incident and prevalent LTOT users because 
of COPD and identifying risk factors associated with excess 
mortality.
Patients and methods
study design and patients
This is a population-based prospective cohort study includ-
ing all patients with COPD requiring LTOT in the canton 
of Bern, Switzerland, between March 2012 and April 2014. 
At that time, all patients on LTOT in the canton of Bern 
were supplied and cared for by the Lungenliga Bern (LLB), 
an independent nonprofit organization engaged in providing 
medical, medico-technical and nursing services to patients 
with chronic and acute lung diseases and participating in 
prevention and promotion of respiratory health. One of 
the LLB’s primary services is the management of LTOT. 
Prescriptions are made and renewed yearly by respiratory 
specialists in conformity with national and international 
guidelines1,25,26 and sent to LLB, where patient data are reg-
istered. LLB is responsible for providing oxygen delivery 
device and counseling for the patient.
Data collection
Baseline data were derived from fully anonymized copies 
of the last prescription form of all patients on LTOT in the 
canton of Bern as per March 12, 2012. Every prescription 
had been annotated with an identity number by LLB and 
we were blinded to all personal information. Baseline data 
included age, sex, diagnosis, presence of cor pulmonale, 
pulmonary function tests, arterial blood gas analysis with 
and without supplemental oxygen at rest and during exertion, 
type of oxygen delivery system and prescribed oxygen dose. 
Rental date of the oxygen delivery device was considered 
as beginning date of LTOT, as this date always coincides 
with the delivery of the device and patient’s instruction. 
Information about the oxygen dose effectively used by each 
patient documented in home visit protocols by the LLB was 
additionally supplied. Compliance with oxygen therapy 
was defined as using oxygen dose as prescribed or for $16 
hours/day. Type 2 respiratory failure was defined as oxygen 
partial pressure (PaO
2
) ,60 mmHg and carbon dioxide 
partial pressure (PaCO
2
) .55 mmHg. Death events were 
reported on a regular basis by the LLB using the provided 
prescription identity number. Data on vital status were pro-
spectively collected for a 2-year period (March 2012–April 
2014). This study was performed in accordance with Swiss 
laws (Federal Act on Research involving Human Beings 
810.30) and the principles of good clinical practice. At the 
time of study design and realization, studies only using fully 
anonymized health data were not subject to legal restrictions. 
Thus, written informed consent was not required as only 
anonymized, already existing data were used.
Eligible were all patients aged .18, receiving LTOT 
because of COPD. Patients who started LTOT within 6 months 
prior to data collection were accounted for as incident users. 
Patients receiving LTOT for longer than 6 months were 
defined as prevalent users.
statistical analysis
To compare mortality rates of patients with COPD receiving 
LTOT and the general population of the Canton of Bern, we 
calculated standardized mortality ratios (the ratio of observed 
to expected number of deaths) and the corresponding 95% con-
fidence interval (CI). Expected numbers of deaths according 
to age (in 10-year age bands) and sex were derived from the 
Swiss Federal Statistical Office 2012 mortality data (https://
www.bfs.admin.ch/bfs/en/home/statistics/health/state-health/
mortality-causes-death.html). Using age- and sex-adjusted 
standardized mortality ratios, we analyzed all-cause mortal-
ity according to patient characteristics at baseline (sex, age, 
type 2 respiratory failure, cor pulmonale, PaO
2
 at rest while 
breathing room air #60 mmHg, PaCO
2
 at rest while breath-
ing room air $55 mmHg, PaO
2
 after 30 min supplemental 
oxygen #60 mmHg, PaCO
2
 after 30 min supplemental oxy-
gen $55 mmHg) using two-sided Z-tests. Missing data were 
accounted for by using multiple imputation according to Rubin’s 
rules, with age, sex, recommended oxygen dose, compliance 
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with the prescribed oxygen dose, whether the patient died, 
presence of cor pulmonale, presence of type 2 respiratory fail-
ure, PaO
2
 and PaCO
2
 at rest while breathing room air and after 
30 min of supplemental oxygen, to create 10 imputed datasets 
using chained equations. To address immortal time bias in 
prevalent cases,27 data for incident and prevalent LTOT users 
were analyzed separately throughout.
In an age- and sex-adjusted multivariable Cox regres-
sion model, we examined the hazard of death in the incident 
and prevalent LTOT groups. Additionally, we performed a 
logistic regression for the age-related probability of death 
of both groups and compared it with the mortality pattern 
of the general population of the canton of Bern (Swiss 
Federal Statistical Office, https://www.bfs.admin.ch/bfs/
en/home/statistics/health/state-health/mortality-causes-
death.html) using the age band of the study population. All 
p-values ,0.05 were considered significant.
Results
Patients’ characteristics and lTOT 
prevalence
On March 12, 2012, a total of 771 patients were treated 
with LTOT in the Canton of Bern (total population 992,617 
inhabitants [www.be.ch/statistik]). Nine patients (1%) were 
aged ,18 years and 287 patients (37%) had a primary diag-
nosis other than COPD leading to LTOT (Figure 1). The 
remaining 475 (62%) patients complied with the eligibility 
criteria and were included. Accordingly, the prevalence of 
LTOT because of COPD was 47.9/100,000 inhabitants. 
Ninety three patients (20%) who had recently started LTOT 
(,6 months prior to the reference date) were considered 
incident users. Three hundred eighty two patients (80%) who 
had been treated with LTOT for longer than 6 months were 
considered prevalent users.
Figure 1 Flow of participants through different stages of the study.
Abbreviations: COPD, chronic obstructive pulmonary disease; lTOT, long-term oxygen therapy.
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Baseline characteristics according to group assignment 
and survival status at the end of follow-up are shown in 
Table 1. Overall, the cohort comprised patients with COPD 
GOLD Stages 2–4 with a mean age of 69±10 years; 68% were 
male. Mean forced expiratory volume in 1 second (FEV
1
) was 
43.1%±17.1% predicted and 243 patients (65%) presented 
with a concomitant cor pulmonale. The LTOT compliance 
was 70% with no significant differences between the two 
groups. At baseline, 88 patients (21%) presented with a 
PaO
2
 .60 mmHg while breathing room air, 18 patients (4%) 
were hypercapnic (PaCO
2
 .55 mmHg) while breathing room 
air and 35 patients (11%) developed hypercapnia on LTOT. 
No patient was lost to follow-up and LTOT was continued 
in all patients during the study period.
Mortality
At the end of the 2-year follow-up period, 140 patients (29%) 
had died. Mortality was significantly higher in incident 
compared to prevalent LTOT users (41% versus 27%; 
p=0.007). In age- and sex-adjusted analyses, this was con-
firmed (hazard ratio =1.66, 95% CI: 1.14–2.41, p=0.008). 
The number of observed and expected deaths and the 
corresponding age- and sex-standardized mortality ratios 
for each variable are shown in Figure 2 for both groups. The 
increase in age- and sex-standardized all-cause mortality 
appeared more pronounced in incident than in prevalent 
LTOT users, even though CI overlapped widely (standard-
ized mortality ratio 8.02 [95% CI: 5.64–11.41] versus 5.90 
[95% CI: 4.79–7.25], respectively).
risk factors
In the incident LTOT group, the standardized mortality ratio 
was significantly higher in patients with type 2 respiratory 
failure at LTOT initiation (60.57 [95% CI: 11.82–310.45] 
versus 7.32 [95% CI: 4.97–10.79], p=0.038) and in patients 
aged ,65 years as compared with older patients (23.38 
[95% CI: 11.94–45.75] versus 6.50 [95% CI: 4.29–9.84], 
p=0.005). We found little evidence to suggest that age- 
standardized mortality ratios differed between men and 
women. Neither presence of cor pulmonale nor isolated 
hypoxemia nor hypercapnia had a significant influence on 
the standardized mortality ratios.
Among prevalent LTOT users, the standardized mortality 
ratio was again significantly higher in patients aged ,65 years 
as compared with older patients (11.35 [95% CI: 7.29–17.65] 
versus 5.24 [95% CI: 4.14–6.65], p=0.008), while sex, the 
Table 1 Patients’ characteristics at baseline
All patients 
(n=475)
Incident LTOT users (n=93) Prevalent LTOT users (n=382) p-value
Patients alive Patients died Patients alive Patients died
n=55 (59%) n=38 (41%) n=280 (73%) n=102 (27%)
age (years) 69.0±10.0 71.1±9.9 71.8±8.4 66.8±10.2 72.7±8.5 ,0.001 
elderly (.65 years of age) 296 (62%) 36 (65%) 28 (74%) 151 (54%) 81 (79%) ,0.001 
sex (male) 323 (68%) 38 (69%) 30 (79%) 184 (66%) 71 (70%) 0.405
Oxygen delivery device
liquid oxygen 211 (44%) 14 (25%) 4 (11%) 147 (53%) 46 (45%) ,0.001
Concentrator 264 (56%) 41 (75%) 34 (89%) 133 (48%) 56 (55%) ,0.001
Data available, 
value*
Data available, 
value*
Data available, 
value*
Data available, 
value*
Data available, 
value*
Cor pulmonale 373, 243 (65%) 48, 29 (60%) 31, 16 (52%) 214, 143 (67%) 80, 55 (69%) 0.296
Vital capacity (%) 411, 64.0±22.9 49, 58.9±24.3 33, 63.8±22.0 243, 64.8±22.2 86, 64.8±24.1 0.417
FeV1 (%) 417, 43.1±17.1 51, 45.9±18.1 34, 40.0±15.2 246, 42.4±16.5 86, 44.7±18.9 0.306
PaO2 at rest while breathing 
room air #60 mmhg
424, 336 (79%) 51, 43 (84%) 33, 24 (73%) 252, 201 (80%) 88, 68 (77%) 0.594
PaCO2 at rest while breathing 
room air $55 mmhg
423, 18 (4%) 50, 1 (2%) 34, 4 (12%) 251, 9 (4%) 88, 4 (5%) 0.131
PaO2 after 30 min supplemental 
oxygen #60 mmhg
315, 54 (17%) 36, 9 (25%) 22, 3 (14%) 186, 28 (15%) 71, 14 (20%) 0.447 
PaCO2 after 30 min supplemental 
oxygen $55 mmhg
317, 35 (11%) 36, 3 (8%) 23, 5 (22%) 187, 21 (11%) 71, 6 (8%) 0.329 
Oxygen dose at rest (l) 457, 2.0±1.0 53, 2.1±1.2 37, 2.0±0.9 268, 1.9±0.8 99, 2.3±1.4 0.003
Type 2 respiratory failure 424, 15 (4%) 51, 1 (2%) 33, 2 (6%) 252, 8 (3%) 88, 4 (5%) 0.718
Compliance to lTOT 475, 333 (70%) 55, 36 (65%) 38, 26 (68%) 280, 191 (68%) 102, 80 (78%) 0.215
Notes: Type 2 respiratory failure was defined as PaO2 ,60 mmhg and PaCO2 .55 mmhg. *Values are mean with a standard deviation for continuous variables and 
percentage for categorical variables.
Abbreviations: FeV1, forced expiratory volume in 1 second; lTOT, long-term oxygen therapy; PaCO2, carbon dioxide partial pressure; PaO2, oxygen partial pressure.
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presence of type 2 respiratory failure, cor pulmonale, isolated 
hypoxemia and hypercapnia did not result in significant dif-
ferences in standardized mortality ratios. In neither cohort, 
there was an association between initial FEV
1
 and compliance 
to LTOT with mortality (data not shown).
Mortality patterns
The age-specific probability of death of incident and preva-
lent LTOT users compared with the general population is 
shown in Figure 3. The mortality pattern of incident LTOT 
users showed a linear association with slow progression and 
Figure 2 age- and sex-standardized mortality ratios for incident lTOT users (A) and prevalent lTOT users (B).
Abbreviations: CI, confidence interval; LTOT, long-term oxygen therapy; PaCO2, carbon dioxide partial pressure; PaO2, oxygen partial pressure; sMr, standardized 
mortality ratio.
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a broad distribution of the CIs with disproportionately high 
mortality in younger age bands. In the prevalent LTOT group, 
the probability of death was at its lowest with younger age 
(40–50) and rose steadily thereafter. The age-related prob-
ability of death of the prevalent LTOT users corresponded to 
the mortality pattern of the general population yet remaining 
higher at any age.
Discussion
Main results
In the current study, we found a disproportionately high 
mortality shortly after initiation of LTOT compared with 
the general population in one of the largest cohorts of COPD 
patients on LTOT during a 2-year follow-up. We found 
different age-related mortality patterns for incident and 
prevalent LTOT users compared with the general population. 
Type 2 respiratory failure was identified as an independent 
risk factor for excess mortality in both the incident and the 
prevalent LTOT group.
strengths and limitations
Strengths of the present study include the population-based 
design and the large size of the cohort. No patient was lost 
to follow-up and no LTOT was discontinued. The inclusion 
Figure 3 age-related probability of death among incident lTOT users (A) and prevalent lTOT users (B).
Abbreviation: lTOT, long-term oxygen therapy.
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of patients receiving LTOT outside current international 
guidelines represents everyday practice and the results of 
our study are based on real-life data.28,29 The analysis was 
adjusted for age and sex and missing data accounted for using 
multiple imputation. One limitation of the study consists 
in the inclusion of patients with different LTOT durations. 
A combination of incident and prevalent LTOT users would 
result in immortal time bias:27 patients in the prevalent LTOT 
group lived long enough to be included in the cohort, giving 
them a survival advantage over the incident LTOT users. 
Therefore, we analyzed incident and prevalent LTOT users 
separately. Another limitation is the lack of data on comor-
bidities and cause of death in our population. This is owed to 
the fact that only fully anonymized data derived from LTOT 
prescription forms were used and information on these issues 
was not part of the LTOT prescription procedure. In addition, 
information on simultaneously administered medication was 
not available. However, as guidelines for LTOT prescription 
in Switzerland require optimized treatment of the underlying 
disease prior to LTOT initiation and reimbursement by 
compulsory health insurances, we believe that the impact 
of comedication on the outcome can be neglected. Finally, 
information on the use of noninvasive ventilation in hyper-
capnic patients was missing, and therefore, its association 
with mortality could not be examined.
Context
The prevalence of LTOT because of COPD in our study 
was identical to a recent report.30 The overall mortality rate 
of incident LTOT users at 2 years in our study was some-
what lower compared to most older cohorts of similar size 
(41% versus 46%–62%),16–19 in accordance with the observed 
declining mortality rates of COPD populations in the last 
two decades.31,32 Two earlier studies showed lower mortality 
rates (22% and 27%) but investigated a much smaller popula-
tion and did not distinguish between incident and prevalent 
LTOT users.14,24 The trend toward mortality reduction over 
time could be due to declining smoking rates and improving 
management of patients with an end-stage pulmonary disease 
and relevant comorbidities over the years. Geographical dif-
ferences (the referred studies were conducted in Australia, 
Belgium, Denmark, Italy, Norway and Sweden), including 
patient characteristics and health care providing, could 
further explain the wide range of mortality rates.
As expected, the standardized mortality ratios of oxygen-
dependent COPD patients (both incident and prevalent LTOT 
users) in the present study were notably higher than the 
reported standardized mortality ratios of an overall COPD 
cohort comprising GOLD stages 2–4 (Table 2). The lack of 
statistically significant differences of standardized mortality 
ratios between males and females in our cohort was inconsis-
tent with current literature but the nominally higher standard-
ized mortality ratios in female prevalent LTOT users seem to 
support recent findings.33 It has been shown that sex-related 
differences in survival become more apparent after 3 years 
of follow-up, meaning that the duration of our study might 
not have been long enough to detect them.23 Other studies, 
however, show a clear survival advantage for women.14,16,20,30 
Heterogeneous population characteristics, the abovemen-
tioned geographic differences and inconsistent covariates in 
the analysis could offer a possible explanation.
risk factors
As discussed above, immortal time bias resulted in preva-
lent LTOT users having lower standardized mortality ratios 
than incident LTOT users. Therefore, the relatively benign 
prognosis of prevalent users lacks credibility. Conversely, 
the disproportionately high standardized mortality ratio of 
incident LTOT users truly reflects the poor prognosis of end-
stage COPD with development of severe hypoxemia requir-
ing LTOT. A large number of incident LTOT users seem to 
be at high risk shortly after LTOT initiation. The survivors 
of this initial period will likely have a prognosis similar to 
the prognosis of the prevalent LTOT users in our study. 
Earlier studies showed an association between older age and 
mortality,16–18,24 whereas our study, in accordance to newer 
data, does not.8,11,23 We found higher standardized mortality 
ratios for patients aged #65 in both incident and prevalent 
LTOT groups. Undoubtedly, this also should be regarded 
as immortal time bias in elderly prevalent users. Among 
incident LTOT users, however, the disproportionately high 
mortality of younger patients aged 40–50 truly reflects the 
higher risk of this group, with a more pronounced risk factor 
profile and/or a worse genetic predisposition that eventu-
ally resulted in an earlier initiation of LTOT during the life 
course. As younger adults are accustomed to higher PaO
2
,34,35 
Table 2 Differences of the standardized mortality ratios of 
oxygen-dependent COPD patients from our cohort compared 
with an overall COPD population
Standardized mortality ratios
Incident 
LTOT users
Prevalent 
LTOT users
Overall COPD 
population33
Female 5.62 7.78 2.7
Male 9.05 5.33 4.8
Abbreviations: COPD, chronic obstructive pulmonary disease; lTOT, long-term 
oxygen therapy.
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mortality could be explained by the greater difference of 
PaO
2
 in severe hypoxemia and a poorer adaptation to the 
impaired gas exchange.
FEV
1
 is an independent prognostic factor associated with 
mortality in the overall COPD population.36 Earlier studies 
found an association between FEV
1
 and mortality in COPD 
patients on LTOT.16,24 However, results from more recent 
cohorts as well as our study do not support this finding.8,23 
We suppose that obstruction severity loses its prognostic 
value in oxygen-dependent COPD patients and that mortal-
ity in this population is influenced by other factors, such 
as impaired gas exchange, recurrent exacerbations and/or 
comorbidities. Cor pulmonale in COPD is considered a 
predictor of poor survival and diminished exercise capacity. 
PaO
2
 cutoffs for prescribing LTOT are higher in this sub-
group of patients.1,25,26 Interestingly, no differences in the 
mortality of patients with and without cor pulmonale were 
observed in our study, suggesting that correcting hypoxemia 
diminishes the additional risk in this subgroup. Improvement 
in pulmonary hemodynamics and a reduction in pulmonary 
vascular resistance by LTOT have been shown as a possible 
underlying pathophysiologic mechanism.37 Consistent with 
previous findings,16 persistent hypoxemia under LTOT did 
not have an influence on mortality in our cohort. Finally, 
we found nominally higher standardized mortality ratios in 
incident LTOT users with PaO
2
 .60 mmHg at rest while 
breathing room air.
Clinical and scientific implications
The disproportionately high mortality of incident LTOT users 
calls for a closer follow-up and more proactive management 
of COPD patients in the first months after prescribing LTOT. 
Deterioration of blood gases is commonly observed during 
acute exacerbations of COPD with PaO
2
 remaining low even 
after clinical stabilization of the patient, leading to the pre-
scription of LTOT.38 A recent study demonstrated a higher 
all-cause 12-month mortality rate in an overall population 
of patients with acute exacerbations of COPD, which sup-
ports our findings.39 We identified type 2 respiratory failure 
at baseline as a risk factor associated with excess mortality. 
Chronic type 2 respiratory failure in COPD is a combina-
tion of hypercapnia because of impairment of the ventila-
tory pump (hyperinflation of the lungs, respiratory muscle 
weakness, pulmonary cachexia) and hypoxemia caused by 
alveolar hypoventilation. An acute event, such as an exac-
erbation associated with an increase of airway obstruction 
and respiratory workload, could disturb the delicate steady 
state of the underlying chronic respiratory failure with further 
impairment of gas exchange that eventually leads to death. 
Type 2 respiratory failure itself results in increased work of 
ventilation with reduced oxygen supply to the respiratory 
muscles creating a vicious cycle.
Chronic hypercapnia alone was not identified as a risk 
factor in the current study but it causes symptoms such as 
anxiety, dyspnea, fatigue, daytime sleepiness, depression 
and confusion. Therefore, it should be prevented by close 
monitoring and adapting oxygen dose after initiation of 
LTOT. Noninvasive ventilation use in the subgroup of COPD 
patients with chronic hypercapnia or type 2 respiratory 
failure should also be considered, as suggested before.40–43 
Even though not statistically significant, our results of higher 
standardized mortality ratios in incident LTOT users with 
PaO
2
 .60 mmHg at rest while breathing room air are alerting. 
They suggest that usage of LTOT in patients presenting only 
with exercise-induced hypoxemia, nocturnal hypoxemia or 
in cases not conforming to international guidelines on the 
prescription of LTOT could be problematic. Further studies 
are needed to confirm these results that could be explained 
by oxygen toxicity and/or by a suppression of the central 
ventilatory drive.
Conclusion
Two-year mortality rate of COPD patients on incident LTOT 
was somewhat lower in our study than in older cohorts 
but remained high compared to the general population, 
especially in younger patients receiving LTOT ,6 months. 
Therefore, patients recently started on LTOT should receive 
a closer follow-up in the first months including reevaluation 
of compliance and indication for oxygen therapy as well 
as adjustment of the oxygen dose according to blood gas 
analysis. LTOT should aim for correction of hypoxemia 
without causing hypercapnia. Closer attention should be 
paid to type 2 respiratory failure that was associated with 
mortality. Noninvasive ventilation should be considered early 
in the management plan of selected patients.
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